This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Akili Toekomstige groei

Future criteriumcontroles 2/6

Akili is forecast to grow revenue at 44.2% per annum.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare Services winstgroei	0%
Inkomstengroei	44.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	21 Jun 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BMV:AKLI * - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	9	N/A	N/A	N/A	1
12/31/2025	6	N/A	N/A	N/A	1
12/31/2024	4	N/A	N/A	N/A	1
3/31/2024	2	-49	-49	-49	N/A
12/31/2023	2	-59	-58	-58	N/A
9/30/2023	1	-65	-70	-70	N/A
6/30/2023	0	2	-73	-73	N/A
3/31/2023	0	-14	-80	-80	N/A
12/31/2022	0	-19	-84	-84	N/A
9/30/2022	0	-26	-81	-81	N/A
6/30/2022	0	-99	-75	-74	N/A
3/31/2022	0	-144	-68	-67	N/A
12/31/2021	1	-127	-54	-54	N/A
9/30/2021	0	-111	-43	-42	N/A
12/31/2020	4	-26	-25	-25	N/A
12/31/2019	20	-21	-30	-29	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if AKLI *'s forecast earnings growth is above the savings rate (7.8%).

Winst versus markt: Insufficient data to determine if AKLI *'s earnings are forecast to grow faster than the MX market

Hoge groeiwinsten: Insufficient data to determine if AKLI *'s earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: AKLI *'s revenue (44.2% per year) is forecast to grow faster than the MX market (6.9% per year).

Hoge groei-inkomsten: AKLI *'s revenue (44.2% per year) is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if AKLI *'s Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Akili Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Reduce Workforce

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

High number of new and inexperienced directors

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

High number of new and inexperienced directors

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven